Advertisement
Screener

Pulse Biosciences, Inc. (PLSE) Selling, General and Administrative Expense

2.8 / 5 stars · 68/120 Roast Me

Pulse Biosciences, Inc. Selling, General and Administrative Expense

Pulse Biosciences, Inc. (PLSE) reported Selling, General and Administrative Expense of $8.46 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-06

  • Pulse Biosciences, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $8.46M, a 3.30% increase year-over-year.
  • Pulse Biosciences, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $6.59M, a 14.75% decline year-over-year.
  • Pulse Biosciences, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $7.33M, a 23.64% decline year-over-year.
  • Pulse Biosciences, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $8.78M, a 47.53% increase year-over-year.
  • Pulse Biosciences, Inc. selling, general and administrative expense for fiscal 2025 was $32.03M, a 33.89% increase from fiscal 2024.
  • Pulse Biosciences, Inc. selling, general and administrative expense for fiscal 2024 was $23.92M.
Period endSelling, General and Administrative Expense 3 monthSelling, General and Administrative Expense 6 monthSelling, General and Administrative Expense 9 monthSelling, General and Administrative Expense 12 month
2026-06-30$8.46M
10-Q · filed 2026-08-06
$15.05M
10-Q · filed 2026-08-06
$22.38M
derived: sum of 3 quarters · filed 2026-08-06
$31.16M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$6.59M
10-Q · filed 2026-05-14
$13.92M
derived: sum of 2 quarters · filed 2026-05-14
$22.70M
derived: sum of 3 quarters · filed 2026-05-14
$30.89M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$7.33M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
$16.11M
derived: sum of 2 quarters · filed 2026-02-19
$24.30M
derived: sum of 3 quarters · filed 2026-08-06
$32.03M
10-K · filed 2026-02-19
2025-09-30$8.78M
10-Q · filed 2025-11-05
$16.97M
derived: sum of 2 quarters · filed 2026-08-06
$24.70M
10-Q · filed 2025-11-05
$34.30M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$8.19M
10-Q · filed 2026-08-06
$15.92M
10-Q · filed 2026-08-06
$25.52M
derived: sum of 3 quarters · filed 2026-08-06
$31.47M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$7.73M
10-Q · filed 2026-05-14
$17.33M
derived: sum of 2 quarters · filed 2026-05-14
$23.28M
derived: sum of 3 quarters · filed 2026-05-14
2024-12-31$9.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
$15.55M
derived: sum of 2 quarters · filed 2026-02-19
$23.92M
10-K · filed 2026-02-19
2024-09-30$5.95M
10-Q · filed 2025-11-05
$14.32M
10-Q · filed 2025-11-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
iRhythm Holdings, Inc. (IRTC)United States$3.651B-281.06
ICU MEDICAL INC/DE (ICUI)United States$4.153B18.85
Heartflow, Inc. (HTFL)United States$4.225B
AtriCure, Inc. (ATRC)United States$3.089B
HAEMONETICS CORP (HAE)United States$4.821B36.52
UFP TECHNOLOGIES INC (UFPT)United States$2.308B28.37
TELEFLEX INC (TFX)United States$5.093B-5.44
MERIT MEDICAL SYSTEMS INC (MMSI)United States$5.212B28.44
Inspire Medical Systems, Inc. (INSP)United States$1.990B9.55
NovoCure Ltd (NVCR)$1.886B-11.87